Market Runner: Could Ardelyx Inc See a Reversal After This Very Strong Session?

Market Runner: Could Ardelyx Inc See a Reversal After This Very Strong Session?

The stock of Ardelyx Inc (NASDAQ:ARDX) is a huge mover today! The stock increased 3.93% or $0.6 on November 29, hitting $15.85. About 114,312 shares traded hands. Ardelyx Inc (NASDAQ:ARDX) has risen 82.20% since April 26, 2016 and is uptrending. It has outperformed by 76.94% the S&P500.
The move comes after 5 months positive chart setup for the $737.64 million company. It was reported on Nov, 29 by We have $17.12 PT which if reached, will make NASDAQ:ARDX worth $59.01M more.

Analysts await Ardelyx Inc (NASDAQ:ARDX) to report earnings on March, 3. They expect $-0.63 EPS, up 3.08% or $0.02 from last year’s $-0.65 per share. After $-0.65 actual EPS reported by Ardelyx Inc for the previous quarter, Wall Street now forecasts -3.08% EPS growth.

Ardelyx Inc (NASDAQ:ARDX) Ratings Coverage

Out of 5 analysts covering Ardelyx Inc (NASDAQ:ARDX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ardelyx Inc has been the topic of 7 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The stock of Ardelyx Inc (NASDAQ:ARDX) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock of Ardelyx Inc (NASDAQ:ARDX) has “Buy” rating given on Tuesday, September 22 by BTIG Research. The firm has “Buy” rating by Ladenburg Thalmann given on Thursday, March 31. On Thursday, September 3 the stock rating was maintained by Wedbush with “Buy”. Citigroup maintained Ardelyx Inc (NASDAQ:ARDX) on Wednesday, August 10 with “Buy” rating. BTIG Research initiated it with “Buy” rating and $33 target price in Friday, December 18 report.

According to Zacks Investment Research, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.”

More notable recent Ardelyx Inc (NASDAQ:ARDX) news were published by: which released: “Ardelyx Inc. NASDAQ: ARDX” on June 19, 2014, also with their article: “Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress” published on November 07, 2016, published: “Ardelyx Strengthens Executive Leadership with the Appointment of Reginald …” on October 24, 2016. More interesting news about Ardelyx Inc (NASDAQ:ARDX) were released by: and their article: “Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016” published on October 31, 2016 as well as‘s news article titled: “Ardelyx Inc. ARDX (US: Nasdaq)” with publication date: May 22, 2013.

ARDX Company Profile

Ardelyx, Inc., incorporated on October 18, 2007, is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Firm operates through research, development and commercialization of biopharmaceutical products segment. The Firm has developed drug discovery and design platform to discover and design drug candidates. Utilizing its platform, the Company has discovered and designed its lead product candidate, tenapanor. The Company’s development programs also include RDX009 Program, RDX013 Program and RDX011 Program. The Firm also owns NaP2b inhibitor compounds. NaP2b is an intestinal transporter of dietary phosphorus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment